The availability of DUOBRII in Quebec's public drug plan means that a larger patient population now has access to the treatment, which could lead to increased sales. As Quebec represents a significant portion of the Canadian market, this expansion is likely to have a positive impact on Bausch Health's short-term revenue. The news is directly related to BHC and its product, hence the high relevance and importance scores. The confidence score reflects the typical positive market reaction to expanded market access for pharmaceutical products.